首页> 外文期刊>World Allergy Organization Journal >Clinical Efficacy and Safety of a Combined Loratadine-Betamethasone Oral Solution in the Treatment of Severe Pediatric Perennial Allergic Rhinitis
【24h】

Clinical Efficacy and Safety of a Combined Loratadine-Betamethasone Oral Solution in the Treatment of Severe Pediatric Perennial Allergic Rhinitis

机译:氯雷他定-倍他米松联合口服液治疗小儿常年性变应性鼻炎的临床疗效和安全性

获取原文
       

摘要

Background Allergic rhinitis is a highly prevalent condition, particularly among children, whose schoolwork and quality of life may be impaired by its symptoms. Methods In this prospective, multicenter study, children between 6 and 12 years old with a diagnosis of severe perennial allergic rhinitis received a combination of the nonsedating antihistamine loratadine and the corticosteroid betamethasone in an oral solution for 5 days. Results The total nasal and ocular symptom score was significantly reduced from 11.4 (± 2.1) before treatment to 2.9 (± 2.4) after treatment (P P Conclusions The combination of loratadine and betamethasone in an oral solution was safe and effective as initial short-term treatment for symptoms of severe perennial allergic rhinitis in school-aged children.
机译:背景过敏性鼻炎是一种高度流行的疾病,尤其是在儿童中,其症状可能会影响其学业和生活质量。方法在这项前瞻性,多中心研究中,诊断为常年性常年性变应性鼻炎的6至12岁儿童在口服溶液中接受了非镇静抗组胺氯雷他定与皮质类固醇倍他米松的联合治疗,持续5天。结果总的鼻和眼症状评分从治疗前的11.4(±2.1)显着降低到治疗后的2.9(±2.4)(PP结论)氯雷他定和倍他米松联合口服溶液作为初始短期治疗是安全有效的学龄儿童严重常年性变应性鼻炎的症状。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号